CMPX earnings: next report 2026-08-10, real EPS beat/miss history, analyst consensus Buy, P/E -4.80. Updated 2026-07-23.
Compass Therapeutics (CMPX) Research Hub
Compass Therapeutics (CMPX) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 2 USD (-8.26%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -4.80, market cap 0.28B. This hub links to the full technical, earnings and options research available for CMPX.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 2 USD (-8.26%) |
| 52-week range | 1.86 USD – 2.55 USD |
| Trend regime | Range |
| 14-day RSI | 43.8 (Bearish) |
| Trailing P/E | -4.80 |
| Market cap | 0.28B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-10 |
Available research for CMPX
Covered Call on CMPX: how it works, illustrative setup around the real 2 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on CMPX: how it works, illustrative setup around the real 2 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on CMPX: how it works, illustrative setup around the real 2 USD price, max profit/loss, breakeven and when to use it. Educational.
CMPX technical analysis: range, last 2 USD, RSI 43.8, 52w range 1.86 USD–2.55 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is CMPX in?
Compass Therapeutics (CMPX) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is CMPX in an uptrend or downtrend?
As of 2026-09-11, CMPX is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is CMPX's trailing P/E ratio?
CMPX's trailing P/E is -4.80, with a market cap of 0.28B. See the earnings research page for full valuation detail.
When does CMPX next report earnings?
CMPX is next scheduled to report earnings on 2026-08-10, with a consensus EPS estimate of -0.1 USD.